Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7702552 | 0.75 | CA1 (0.43) | CES2CES1CA1CA2CA4 | |
| SCHEMBL41646 | 0.75 | CA1 (0.43) | CES2CES1CA1CA2CA4 | |
| Formaldehyde SCHEMBL27280878 | 0.73 | CA1 (0.43) | CES2CES1CA1CA2CA4 | |
| SCHEMBL2844279 | 0.73 | CES2 (0.48) | CES2CES1CA1CA2CA4 | |
| SCHEMBL23589702 | 0.72 | CA1 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL29061953 | 0.72 | CA1 (0.41) | CES2CES1CA1CA2CA4 | |
| Bromide SCHEMBL6247121 | 0.72 | CA1 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL31540317 | 0.72 | CA1 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL29061954 | 0.72 | CA1 (0.41) | CES2CES1CA1CA2CA4 | |
| SCHEMBL29576072 | 0.72 | CA1 (0.41) | CES2CES1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20240115719-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-04-11 | — | — | US | claimed |
| EP-3870044-B1 | COMPLEXES AND LIGANDS | MASSACHUSETTS GEN HOSPITAL (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4306535-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED USING SAME | AJINOMOTO CO., INC. (JP) | 2024-01-17 | — | — | EP | claimed |
| US-20240000965-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-01-04 | — | — | US | claimed |
| EP-4279500-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY PRODUCED USING SAME | AJINOMOTO CO., INC. (JP) | 2023-11-22 | — | — | EP | claimed |
| EP-4271997-A1 | METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES | Encodia, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116964076-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-10-27 | — | — | CN | claimed |
| US-20230312471-A1 | CHEMICAL PROBES AND INHIBITORS FOR POLYPEPTIDES OF SARS CORONAVIRUSES | Universität Konstanz (DE) | 2023-10-05 | — | — | US | claimed |
| US-5653958-A | Imidazole based nitrogen-sulfur ligands useful in radiographic imaging agents | MALLINCKRODT MEDICAL, INC. (US) | 1997-08-05 | — | — | US | claimed |
| EP-0689463-A4 | IMIDAZOLE BASED NITROGEN-SULFUR LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS | MALLINCKRODT MEDICAL INC (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0692977-A4 | NOVEL HETEROCYCLE BASED NITROGEN-SULFUR LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS | MALLINCKRODT MEDICAL INC (US) | 1996-04-10 | — | — | EP | claimed |
| EP-0692977-A1 | NOVEL HETEROCYCLE BASED NITROGEN-SULFUR LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0689463-A1 | IMIDAZOLE BASED NITROGEN-SULFUR LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1996-01-03 | — | — | EP | claimed |
| EP-0642357-A4 | RADIOLABELLED PEPTIDE COMPOUNDS. | — | 1995-04-05 | — | — | EP | claimed |
| EP-0642357-A1 | RADIOLABELLED PEPTIDE COMPOUNDS | MALLINCKRODT MEDICAL, INC. (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1994021304-A1 | NOVEL HETEROCYCLE BASED NITROGEN-SULFUR LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| WO-1994020148-A1 | IMIDAZOLE BASED NITROGEN-SULFUR LIGANDS USEFUL IN RADIOGRAPHIC IMAGING AGENTS | MALLINCKRODT MEDICAL, INC. (US) | 1994-09-15 | — | — | WO | claimed |
| WO-1993015770-A1 | RADIOLABELLED PEPTIDE COMPOUNDS | MALLINCKRODT MEDICAL, INC. (US) | 1993-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312471-A1 | CHEMICAL PROBES AND INHIBITORS FOR POLYPEPTIDES OF SARS CORONAVIRUSES | SARS1, ACE, ACE2 | CES2 823/4885CES1 293/4885CA1 2797/4885 |
| US-20240000965-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | IGLV6-57, CD47, SSB | CES2 2762/4885CES1 4076/4885CA1 117/4885 |
| US-20240115719-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | IGLV6-57, SSB, FCGR3B | CES2 3995/4885CES1 4570/4885CA1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.